Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

被引：0

作者：

Makharadze, T. ^{[1
]}

Gogishvili, M. ^{[2
]}

Melkadze, T. ^{[3
]}

Baramidze, A. ^{[3
]}

Giorgadze, D. ^{[4
]}

Penkov, K. D. ^{[5
]}

Laktionov, K. ^{[6
]}

Nemsadze, G. ^{[7
]}

Nechaeva, M. ^{[8
]}

Rozhkova, I. ^{[9
]}

Kalinka, E. ^{[10
]}

Li, S. ^{[11
]}

Li, Y. ^{[11
]}

Kaul, M. ^{[11
]}

Pouliot, J-F. ^{[11
]}

Seebach, F. ^{[11
]}

Lowy, I. ^{[11
]}

Gullo, G. ^{[11
]}

Rietschel, P. ^{[11
]}

机构：

[1] High Technol Hosp Medctr, Batumi, Georgia

[2] High Technol Med Ctr, Tbilisi, Georgia

[3] Acad F Todua Med Ctr, Tbilisi, Georgia

[4] David Tvildiani Med Univ, Tbilisi, Georgia

[5] Private Med Inst Euromedserv, St Petersburg, Russia

[6] Minist Hlth Russian Federat, Fed State Budgetary Inst, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia

[7] Inst Clin Oncol, Tbilisi, Georgia

[8] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia

[9] Kaluga Reg Clin Oncol Dispensary, Kaluga, Russia

[10] Polish Mothers Mem Hosp Res Inst, Lodz, Poland

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S38 / S39

页数：2

共 50 条

[21] CHEMOTHERAPY VERSUS CHEMOTHERAPY PLUS IRRADIATION IN LIMITED SMALL-CELL LUNG-CANCER - RESULTS OF A CONTROLLED TRIAL WITH 5 YEARS FOLLOW-UP
OSTERLIND, K
HANSEN, HH
HANSEN, HS
DOMBERNOWSKY, P
HANSEN, M
RORTH, M
BRITISH JOURNAL OF CANCER, 1986, 54 (01) : 7 - 17
[22] Cemiplimab in association to chemotherapy in advanced non-small cell lung cancer
Rousseau, Adrien
Auclin, Edouard
BULLETIN DU CANCER, 2023, 110 (10)
[23] Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial
Zhigang Wei
Xia Yang
Xin Ye
Qingliang Feng
Yanjun Xu
Licheng Zhang
Wenqiao Sun
Yuting Dong
Qi Meng
Tao Li
Chuntang Wang
Guangxu Li
Kaixian Zhang
Peishun Li
Jingwang Bi
Guoliang Xue
Yahong Sun
Lijun Sheng
Bin Liu
Guohua Yu
Haipeng Ren
Junye Wang
Lijun Sun
Shaoshui Chen
Dianzhong Geng
Benhua Zhang
Xin Xu
Liangming Zhang
Dengjun Sun
Xinglu Xu
Cunqi Diao
Guanghui Huang
Wenhong Li
Xiaoying Han
Jiao Wang
Min Meng
Yang Ni
Aimin Zheng
Weijun Fan
Yuliang Li
Fan Li
Hua Fan
Zhigeng Zou
Qingyu Li
Hui Tian
European Radiology, 2020, 30 : 2692 - 2702
[24] Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial
Wei, Zhigang
Yang, Xia
Ye, Xin
Feng, Qingliang
Xu, Yanjun
Zhang, Licheng
Sun, Wenqiao
Dong, Yuting
Meng, Qi
Li, Tao
Wang, Chuntang
Li, Guangxu
Zhang, Kaixian
Li, Peishun
Bi, Jingwang
Xue, Guoliang
Sun, Yahong
Sheng, Lijun
Liu, Bin
Yu, Guohua
Ren, Haipeng
Wang, Junye
Sun, Lijun
Chen, Shaoshui
Geng, Dianzhong
Zhang, Benhua
Xu, Xin
Zhang, Liangming
Sun, Dengjun
Xu, Xinglu
Diao, Cunqi
Huang, Guanghui
Li, Wenhong
Han, Xiaoying
Wang, Jiao
Meng, Min
Ni, Yang
Zheng, Aimin
Fan, Weijun
Li, Yuliang
Li, Fan
Fan, Hua
Zou, Zhigeng
Li, Qingyu
Tian, Hui
EUROPEAN RADIOLOGY, 2020, 30 (05) : 2692 - 2702
[25] Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial Response
Makharadze, Tamta
Gogishvili, Miranda
Baramidze, Ana
Li, Siyu
Li, Yuntong
Pouliot, Jean-Francois
Seebach, Frank
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (07) : E74 - E75
[26] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial
Ozguroglu, Mustafa
Kilickap, Saadettin
Sezer, Ahmet
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Nechaeva, Marina
Schenker, Michael
Cicin, Irfan
Ho, Gwo Fuang
Kulyaba, Yaroslav
Zyuhal, Kasimova
Scheusan, Roxana-Ioana
Garassino, Marina Chiara
He, Xuanyao
Kaul, Manika
Okoye, Emmanuel
Li, Yuntong
Li, Siyu
Pouliot, Jean-Francois
Seebach, Frank
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
LANCET ONCOLOGY, 2023, 24 (09): : 989 - 1001
[27] Chemotherapy and surgery versus surgery alone in non-small cell lung cancer
Burdett, S. S.
Stewart, L. A.
Rydzewska, L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
[28] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more(EMPOWER-Lung 1):35-month follow-up from a multicentre,open-label,randomised,phase 3 trial
Mustafa ?zgüroglu
Saadettin Kilickap
Ahmet Sezer
Mahmut Gümüs
Igor Bondarenko
Miranda Gogishvili
Marina Nechaeva
Michael Schenker
Irfan Cicin
Gwo Fuang Ho
Yaroslav Kulyaba
Kasimova Zyuhal
Roxana-loana Scheusan
Marina Chiara Garassino
Xuanyao He
Manika Kaul
Emmanuel Okoye
Yuntong Li
Siyu Li
Jean-Francois Pouliot
Frank Seebach
Israel Lowy
Giuseppe Gullo
Petra Rietschel
房超
肿瘤药学, 2023, 13 (04) : 384 - 384
[29] Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
Yang, Zu-Yao
Liu, Li
Mao, Chen
Wu, Xin-Yin
Huang, Ya-Fang
Hu, Xue-Feng
Tang, Jin-Ling
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (11):
[30] Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Xu, J. L.
Jin, B.
Ren, Z. H.
Lou, Y. Q.
Zhou, Z. R.
Yang, Q. Z.
Han, B. H.
PLOS ONE, 2015, 10 (07):

← 1 2 3 4 5 →